Valuation: Quest PharmaTech Inc.

Market Cap 3.38M 2.39M 2.13M 1.97M 1.79M 227M 3.44M 23.68M 9.29M 118M 8.97M 8.78M 378M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.09M 2.75M 2.54M 2.31M 293M 4.44M 30.58M 11.99M 153M 11.59M 11.34M 488M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Current month-20.00%
1 month-20.00%
6 months-33.33%
Current year-42.86%
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 A OtherCompany 0 0% -
10/21/25 A Other

Chief Executive Officer

1,000,000 0.5913%
10/21/25 A Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-69.23% 2.38M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.73%+2.58%+29.57%+33.98% 44.61B
-5.72%-6.08%+258.76%+422.36% 40.57B
-1.51%+3.83%+15.73%+111.58% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.52%-9.29%-16.30%-9.30% 22.66B
Average -1.74%+1.37%+34.84%+69.87% 37.97B
Weighted average by Cap. -2.53%+1.65%+45.61%+89.54%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.27M -1.13M -1.05M -954K -121M -1.83M -12.61M -4.94M -63.06M -4.78M -4.68M -201M 5M 3.53M 3.14M 2.91M 2.65M 335M 5.08M 34.99M 13.72M 175M 13.26M 12.98M 558M
Net Debt 795K 562K 500K 463K 421K 53.33M 808K 5.57M 2.18M 27.83M 2.11M 2.06M 88.73M 986K 697K 619K 574K 522K 66.13M 1M 6.9M 2.71M 34.51M 2.62M 2.56M 110M
Projected Income Statement - Annual - Quest PharmaTech Inc.
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
16/10/26 CA$0.0200 0.00% 1,500